U.S. patent application number 12/415945 was filed with the patent office on 2009-10-08 for method and system for noninvasive mastopexy.
Invention is credited to Peter G. Barthe, Inder Raj S. Makin, Michael H. Slayton.
Application Number | 20090253988 12/415945 |
Document ID | / |
Family ID | 36126476 |
Filed Date | 2009-10-08 |
United States Patent
Application |
20090253988 |
Kind Code |
A1 |
Slayton; Michael H. ; et
al. |
October 8, 2009 |
METHOD AND SYSTEM FOR NONINVASIVE MASTOPEXY
Abstract
Methods and systems for noninvasive mastopexy through deep
tissue tightening with ultrasound are provided. An exemplary method
and system comprise a therapeutic ultrasound system configured for
providing ultrasound treatment to a deep tissue region, such as a
region comprising muscular fascia and ligaments. In accordance with
various exemplary embodiments, a therapeutic ultrasound system can
be configured to achieve depth from 1 mm to 4 cm with a conformal
selective deposition of ultrasound energy without damaging an
intervening tissue in the range of frequencies from 1 to 15 MHz. In
addition, a therapeutic ultrasound can also be configured in
combination with ultrasound imaging or imaging/monitoring
capabilities, either separately configured with imaging, therapy
and monitoring systems or any level of integration thereof.
Inventors: |
Slayton; Michael H.; (Tempe,
AZ) ; Barthe; Peter G.; (Phoenix, AZ) ; Makin;
Inder Raj S.; (Mesa, AZ) |
Correspondence
Address: |
SNELL & WILMER L.L.P. (Main)
400 EAST VAN BUREN, ONE ARIZONA CENTER
PHOENIX
AZ
85004-2202
US
|
Family ID: |
36126476 |
Appl. No.: |
12/415945 |
Filed: |
March 31, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11163155 |
Oct 6, 2005 |
7530356 |
|
|
12415945 |
|
|
|
|
60616355 |
Oct 6, 2004 |
|
|
|
Current U.S.
Class: |
600/439 |
Current CPC
Class: |
A61B 8/429 20130101;
A61B 18/04 20130101; A61B 8/483 20130101; A61B 2018/00333 20130101;
A61N 7/02 20130101; G01S 7/52046 20130101; G01S 15/8909 20130101;
A61B 2018/00904 20130101; A61N 2007/0052 20130101; A61B 8/4281
20130101; A61B 18/18 20130101; A61B 2018/00791 20130101; A61B
2018/00642 20130101; A61B 8/14 20130101; A61B 8/0825 20130101; A61B
8/4483 20130101; A61B 8/461 20130101; A61B 2018/00994 20130101;
A61B 2018/00577 20130101 |
Class at
Publication: |
600/439 |
International
Class: |
A61B 8/14 20060101
A61B008/14; A61N 7/00 20060101 A61N007/00 |
Claims
1. An ultrasound system configured for noninvasive mastopexy
comprising: a control system configured for control of said
ultrasound treatment system; an imaging system coupled to said
control system, said imaging system configured for imaging of a
region of interest, said region of interest comprising of a
Cooper's ligament; an ultrasound probe configured for generating a
conformal lesion within said region of interest to facilitate
mastopexy, said control system and said probe being configured to
operate in a frequency range of about 1 MHz to about 15 MHz.
2. The ultrasound system of claim 1, wherein said ultrasound probe
is further configured for spatial and temporal control to generate
said conformal lesion.
3. The ultrasound system of claim 4, wherein said spatial control
comprises selection of one or more spatial parameters comprising
transducer configuration, distance, placement, orientation, and
movement.
4. The ultrasound system of claim 4, wherein said temporal control
comprises selection of one or more temporal parameters comprising
drive amplitude levels, frequency/waveforms, and timing
sequences.
5. The ultrasound system according to claim 1, wherein said control
system comprises: power source components configured to provide
energy to said control system and said ultrasound probe; sensing
and monitoring components configured for monitoring spatial and
temporal parameters; cooling and coupling controls configured to
remove waste heat from said ultrasound probe to facilitate
temperature control at superficial human tissue interface and
deeper into tissue; and processing and control logic components for
overall control of said ultrasound treatment system.
6. The ultrasound system according to claim 1, wherein said
ultrasound probe comprises: a control interface for interfacing
with said control system; a transducer configured for providing
ablative ultrasound energy to said region of interest; coupling
components for acoustically coupling said transducer to said region
of interest; monitoring and sensing components for facilitating
control by said control system; and a motion mechanism comprising
one of manual and automated movement of said ultrasound probe.
7. The ultrasound system according to claim 1, wherein said
ultrasound probe comprises a transducer, said transducer comprising
at least one of a curvilinear array, an annular array, a linear
array, and a planar array.
8. The ultrasound system according to claim 1, wherein said
ultrasound probe comprises an array and at least two focused
transduction elements, wherein said array is at least one of a
linear array, a planar array, and an annular array.
9. The ultrasound treatment system according to claim 8, wherein
said treatment system comprises at least two of an imaging system,
a therapy system, and a treatment monitoring system, wherein said
at least two systems are combined with an auxiliary imaging and
treatment monitoring apparatus and a secondary therapy system.
10. The ultrasound treatment system according to claim 9, wherein
said auxiliary imaging apparatus comprises at least one of a
photographic device and an optical modality.
11. The ultrasound treatment system according to claim 1, wherein
said control system comprises an imaging system configured for
facilitating at least one of one-dimensional imaging,
one-dimensional treatment, two-dimensional imaging, two-dimensional
treatment, three-dimensional imaging, and three-dimensional
treatment.
12. An ultrasound system configured for noninvasive mastopexy
comprising: a control system configured for control of said
ultrasound treatment system; an imaging system coupled to said
control system, said imaging system configured for imaging of a
deep tissue region comprising at least one of muscular fascia, a
ligament, and a Cooper's ligament; and an ultrasound probe
configured for generating a conformal lesion within said region of
interest to facilitate mastopexy, said control system and said
ultrasound probe being configured for spatial and temporal control
to generate said conformal lesion.
13. The ultrasound system of claim 12, wherein said ultrasound
probe and said control system are configured to operate in a
frequency range of about 1 MHz to about 15 MHz.
14. The ultrasound system of claim 12, wherein said spatial control
comprises selection of at least one spatial parameter comprising
transducer configuration, distance, placement, orientation, and
movement.
15. The ultrasound system of claim 12, wherein said temporal
control comprises selection of at least one temporal parameter
comprising a drive amplitude level, a frequency/waveform, and a
timing sequence.
16. The ultrasound system of claim 12, wherein said ultrasound
probe is to provide at least two energy effects to said region of
interest; wherein said at least two energy effects are configured
to facilitate a response in said region of interest, and wherein
said at least two energy effects include at least two of thermal,
cavitational, hydrodynamic, and resonance induced tissue effects
and wherein said response includes at least one of hemostasis,
subsequent revascularization/angiogenesis, growth of
interconnective tissue, tissue reformation, ablation of existing
tissue, enhanced delivery and activation of medicants, stimulation
of protein synthesis and increased cell permeability.
17. A method for providing noninvasive mastopexy, said method
comprising: delivering ultrasound energy from a transducer probe to
a region of interest of a breast comprising a ligament; ablating
said ligament in said region of interest with said ultrasound
energy; and monitoring said region of interest.
18. The method according to claim 17, further comprising imaging
said region of interest of a breast comprising said ligament.
19. A method for providing noninvasive ultrasound mastopexy
treatment, the method comprising: targeting at least a portion of a
treatment area in a breast and below a skin surface, said treatment
area comprising a muscle and a ligament connected to a portion of
breast tissue; delivering ultrasound energy to said at least a
portion of said treatment area at specified depth below said skin
surface; coagulating at least one of said muscle and said ligament
with said ultrasound energy.
20. A method for providing noninvasive mastopexy, said method
comprising: imaging a region of interest of a breast comprising a
ligament; delivering ultrasound energy from a transducer probe to
said region of interest of a breast comprising said ligament;
ablating said ligament in said region of interest with said
ultrasound energy; and tightening a portion of said region of
interest.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/163,155, filed Oct. 6, 2005, which claims
priority to and the benefit of U.S. Provisional Application Ser.
No. 60/616,355, filed on Oct. 6, 2004, both of which are
incorporated by reference herein.
FIELD OF INVENTION
[0002] The present invention relates to ultrasound therapy systems,
and in particular to a method and system for noninvasive
mastopexy.
BACKGROUND
[0003] Coarse sagging of the skin and facial musculature occurs
gradually over time due to gravity and chronic changes in
connective tissue associated with aging. Invasive surgical
treatment to tighten such tissues is common, for example by
face-lifts. In these treatments for connective tissue sagging, a
portion of the tissue is usually removed, and sutures or other
fasteners are used to suspend the sagging tissue structures. On the
breasts, the muscular fascia and ligaments form a layer superficial
to the muscles and beneath the skin and subcutaneous fat. Breast
sagging is due to a process in which the suspensory (Cooper's)
ligaments become lax. Surgical tightening of the underlying
muscular fascia and ligaments is needed for surgical correction
through a procedure referred to as mastopexy, or more commonly
known as breast lifts.
[0004] Radio frequency (RF) devices have been used to produce
heating and shrinkage of skin on the face and breast, with some
success as a non-invasive alternative to surgical lifting
procedures. However, RF is a dispersive form of energy deposition.
It is impossible to control precisely the heated tissue volume and
depth, because resistive heating of tissues by RF energy occurs
along the entire path of electrical conduction through tissues.
Another restriction of RF energy for non-invasive tightening of
Cooper's ligaments is unwanted destruction of the overlying fat and
skin layers. High impedance to RF within fat, overlying the
suspensory connective structures intended for shrinking, leads to
higher temperatures in the fat than in the target suspensory
structures. Similarly, mid-infrared lasers and other light sources
have been used as attempts to non-invasively heat and shrink
connective tissues of the dermis. However, light is not capable of
non-invasive treatment of Cooper's ligaments, because light does
not penetrate deeply enough to produce local heating there. Below a
depth of approximately 1 mm, light energy is multiply scattered and
cannot be focused to achieve precise local heating.
SUMMARY OF THE INVENTION
[0005] In accordance with various aspects of the present invention,
methods and systems for noninvasive breasts lifts through deep
tissue tightening with ultrasound are provided. An exemplary method
and system comprise a therapeutic ultrasound system configured for
providing ultrasound treatment to a deep tissue region, such as a
region comprising muscular fascia and ligaments.
[0006] In accordance with various exemplary embodiments, a
therapeutic ultrasound system can be configured to achieve depth
from 1 mm to 4 cm with a conformal selective deposition of
ultrasound energy without damaging an intervening tissue in the
range of frequencies from 1 to 15 MHz. In addition, a therapeutic
ultrasound can also be configured in combination with ultrasound
imaging or imaging/monitoring capabilities, either separately
configured with imaging, therapy and monitoring systems or any
level of integration thereof.
[0007] An exemplary therapeutic ultrasound system can also be
substantially capable of conformal and localized deposition of
ultrasound energy as well as targeting and/or monitoring
capabilities. Further, a therapeutic ultrasound can also avoid
heating, cavitation or other distractive events in the intervening
tissue that contains vital structures, as well as tissue posterior
to the conformal lesion to avoid the same.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] The subject matter of the invention is particularly pointed
out in the concluding portion of the specification. The invention,
however, both as to organization and method of operation, may best
be understood by reference to the following description taken in
conjunction with the accompanying drawing figures, in which like
parts may be referred to by like numerals:
[0009] FIG. 1 illustrates a block diagram of an exemplary
ultrasound treatment system for noninvasive mastopexy in accordance
with an exemplary embodiment of the present invention;
[0010] FIG. 2 illustrates a cross sectional diagram of an exemplary
probe system in accordance with exemplary embodiments of the
present invention;
[0011] FIGS. 3A and 3B illustrate block diagrams of an exemplary
control system in accordance with exemplary embodiments of the
present invention;
[0012] FIGS. 4A and 4B illustrate block diagrams of an exemplary
probe system in accordance with exemplary embodiments of the
present invention;
[0013] FIG. 5 illustrates a cross-sectional diagram of an exemplary
transducer in accordance with an exemplary embodiment of the
present invention;
[0014] FIGS. 6A and 6B illustrate cross-sectional diagrams of an
exemplary transducer in accordance with exemplary embodiments of
the present invention;
[0015] FIG. 7 illustrates exemplary transducer configurations for
ultrasound treatment in accordance with various exemplary
embodiments of the present invention;
[0016] FIGS. 8A and 8B illustrate cross-sectional diagrams of an
exemplary transducer in accordance with another exemplary
embodiment of the present invention;
[0017] FIG. 9 illustrates an exemplary transducer configured as a
two-dimensional array for ultrasound treatment in accordance with
an exemplary embodiment of the present invention;
[0018] FIGS. 10A-10F illustrate cross-sectional diagrams of
exemplary transducers in accordance with other exemplary
embodiments of the present invention;
[0019] FIG. 11 illustrates a schematic diagram of an acoustic
coupling and cooling system in accordance with an exemplary
embodiment of the present invention; and
[0020] FIG. 12 illustrates a block diagram of a treatment system
comprising an ultrasound treatment subsystem combined with
additional subsystems and methods of treatment monitoring and/or
treatment imaging as well as a secondary treatment subsystem in
accordance with an exemplary embodiment of the present
invention.
DETAILED DESCRIPTION
[0021] The present invention may be described herein in terms of
various functional components and processing steps. It should be
appreciated that such components and steps may be realized by any
number of hardware components configured to perform the specified
functions. For example, the present invention may employ various
medical treatment devices, visual imaging and display devices,
input terminals and the like, which may carry out a variety of
functions under the control of one or more control systems or other
control devices. In addition, the present invention may be
practiced in any number of medical contexts and that the exemplary
embodiments relating to noninvasive mastopexy therapy treatment
systems, imaging systems and monitoring systems as described herein
are merely indicative of exemplary applications for the invention.
For example, the principles, features and methods discussed may be
applied to any medical application. Further, various aspects of the
present invention may be suitably applied to other
applications.
[0022] In accordance with various aspects of the present invention,
a method and system for noninvasive breasts lifts through deep
tissue tightening with ultrasound are provided. For example, in
accordance with an exemplary embodiment, with reference to FIG. 1,
an exemplary treatment system 100 configured to treat a region of
interest 106 comprises a control system 102, an imaging/therapy
probe with acoustic coupling 104, and a display system 108.
[0023] Control system 102 and display system 108 can comprise
various configurations for controlling probe 104 and overall system
100 functionality, such as, for example, a microprocessor with
software and a plurality of input/output devices, system and
devices for controlling electronic and/or mechanical scanning
and/or multiplexing of transducers, a system for power delivery,
systems for monitoring, systems for sensing the spatial position of
the probe and/or transducers, and/or systems for handling user
input and recording treatment results, among others.
Imaging/therapy probe 104 can comprise various probe and/or
transducer configurations. For example, probe 104 can be configured
for a combined dual-mode imaging/therapy transducer, coupled or
co-housed imaging/therapy transducers, or simply a separate therapy
probe and an imaging probe.
[0024] In accordance with an exemplary embodiment, treatment system
100 is configured for treating the superficial layers of tissue of
a breast, e.g., a deep tissue region, such as a region comprising
muscular fascia, ligaments, Cooper's ligaments, suspensory
ligaments, ligaments located underneath the breast tissue, and/or
muscle, fat or dermis regions, by first, imaging of region of
interest 106 for localization of the treatment area and surrounding
structures, second, delivery of ultrasound energy at a depth,
distribution, timing, and energy level to achieve the desired
therapeutic effect, and third to monitor the treatment area before,
during, and after therapy to plan and assess the results and/or
provide feedback.
[0025] As to the treatment of the region comprising muscular fascia
and ligaments, tissue can be permanently tightened by thermal
ablation to temperatures about 60 degrees C. or higher resulting in
the desired lifting of the breast.
[0026] In addition, the muscular fascia and ligaments region is
typically about 1 mm to 4 cm deep, and varies in depth and
thickness at different locations. Techniques for local heating of
regions of the Cooper's ligaments or other suspensory subcutaneous
connective tissue structures to temperatures of about 60-90 C,
without significant damage to overlying, underlying, or surrounding
tissues, are desirable as a noninvasive treatment for sagging.
However, it is undesirable to heat the tissue to temperatures
greater than about 100 degrees C. or higher, which can cause
destructive cavitation (boiling). Unfortunately, previously, no
systems or techniques had been developed yet that provide the
combination of targeted, precise, local heating to a specified
temperature region capable of inducing desired shrinkage of
suspensory connective tissues underlying skin and subcutaneous
fat.
[0027] An exemplary non-invasive mastopexy system overcomes this
issues and provides the combination of targeted, precise, local
heating to a specified temperature region capable of inducing
desired shrinkage of suspensory connective tissues underlying skin
and subcutaneous fat. For example, with reference to an exemplary
embodiment illustrated in FIG. 2, a non-invasive mastopexy system
200 can comprise a therapy transducer system 202, a control system
204 and a display 206 to provide treatment to a region of interest
(ROI) 210. Exemplary transducer system 200 is configured for first,
imaging and display of region of interest 210 for localization of
the treatment area and surrounding structures, second, delivery of
focused, unfocused, or defocused ultrasound energy at a depth,
distribution, timing, and energy level to achieve the desired
therapeutic effect of thermal ablation to treat cellulite, and
third to monitor the treatment area and surrounding structures
before, during, and after therapy to plan and assess the results
and/or provide feedback to control system 204 and/or an
operator.
[0028] Transducer probe 202 may be configured in a probe
arrangement to provide treatment. Transducer probe 202 may also be
configured with various mechanical devices to allow for optimal
treatment and therapy, for example to provide controlled
positioning of ultrasound therapy transducer 202, such as through a
non-invasive configuration and through control by control system
204. Further, transducer probe 202 may also be configured for
one-dimensional, two-dimensional, and/or annular arrays, and/or for
three-dimensional treatment applications such as that described
herein.
[0029] Exemplary transducer probe 202 can be configured to be
suitably controlled and/or operated in various manners. For
example, transducer probe 202 may be configured for use within an
ultrasound treatment system, an ultrasound imaging system, an
ultrasound monitoring system, and/or any combination of an
ultrasound treatment, imaging and/or monitoring system including
motion control subsystems.
[0030] Control system 204 can be configured with one or more
subsystems, processors, input devices, displays and/or the like.
Display 206 may be configured to image and/or monitor ROI 210
and/or any particular sub-region within ROI 210. Display 206 can be
configured for two-dimensional, three-dimensional, real-time,
analog, digital and/or any other type of imaging. Exemplary
embodiments of both control system 204 and display 206 are
described in greater detail herein.
[0031] Region of tissue 210 can comprise a superficial layer, such
as, for example the epidermis and/or dermis, subcutaneous fat,
Cooper ligaments, and/or muscle. Because Cooper's ligaments are
typically about 1 mm to 4 cm deep ROI 210 may comprise an extended
area of interest. Also, because Cooper's ligaments vary in depth
and thickness at different locations, transducer system 200 is
configured to facilitate imaging and treatment at different tissue
depths and locations.
[0032] That is, exemplary transducer system 200, can be configured
to provide cross-sectional two-dimensional imaging of a region 207,
displayed as an image 205, with a controlled thermal lesion 209,
confined within ROI 210. For example, through such spatial and/or
temporal control, an exemplary treatment system 200 can enable the
regions of thermal injury to possess arbitrary shape and size and
allow the tissue to be treated in a controlled manner.
[0033] In accordance with an exemplary embodiment, transducer probe
202 can comprise a variable depth transducer including a
transduction element having a piezoelectrically active layer,
matching layers and/or other materials for generating radiation or
acoustical energy. In other words, transducer probe 202 may be
configured to operate at moderate frequencies to provide variable
depth treatment within ROI 210. Moreover, transducer probe 202 can
also be configured as a multi-directional transducer. Various
configurations of transducer probe 202 are described in detail
herein.
[0034] Exemplary ultrasound transducer probe 202 can be configured
in various manners to provide various functions. In one embodiment,
transducer probe 202 can be configured for generating high acoustic
power for treatment purposes, while also providing for good imaging
capabilities. For example, to allow for the treatment spot size to
be optimally controlled at various treatment depths, an exemplary
embodiment of the present invention may comprise a transducer
configured into an array of sub-elements, each sub-element
configured for processing acoustic waves with a sufficient
bandwidth for good axial resolution.
[0035] For example, an ultrasound therapy transducer system can be
configured for spatial control and/or temporal control by changing
the position of transducer, its drive frequency, focal depth, drive
amplitude, and timing of the exemplary transducer. In accordance
with various exemplary embodiments, transducer probe 202 can be
configured for spatial control, such as by changing the distance
from transducer probe 202 to a reflecting surface, or changing the
angles of energy focused or unfocused to tissue regions 205 and/or
207, and/or configured for temporal control, such as by controlling
changes in the frequency, drive amplitude and timing of transducer
probe 202 through control system 204. As a result, changes in the
location of the treatment region, the shape and size and/or volume
of the spot or region of interest, as well as the thermal
conditions, can be dynamically controlled versus time.
[0036] In addition to the spatial control, control system 204
and/or transducer probe 202 can also be configured for temporal
control, such as through adjustment and optimization of drive
amplitude levels, frequency/waveform selections, and timing
sequences and other energy drive characteristics to control the
treatment of tissue. The spatial and/or temporal control can also
be facilitated through open-loop and closed-loop feedback
arrangements, such as through the monitoring of various positional
and temporal characteristics.
[0037] In accordance with another exemplary embodiment of the
present invention, control system 204 and/or transducer probe 202
can also be configured for generating high acoustic power for
treatment purposes, while also providing for good imaging
capabilities. For example, to allow for the treatment spot size to
be optimally controlled at various treatment depths, an exemplary
embodiment of the present invention may comprise a transducer
configured into an array of sub-elements, each sub-element
configured for processing acoustic waves with a sufficient
bandwidth for good axial resolution such as described in U.S.
application Ser. No. 10/944,500, SYSTEM AND METHOD FOR VARIABLE
DEPTH ULTRASOUND TREATMENT, filed Sep. 16, 2004, having at least
one common inventor, and hereby incorporated by reference.
[0038] In accordance with another aspect of the present invention,
exemplary ultrasound therapy treatment system 200 may also be
configured to provide therapeutic heating, cooling and/or imaging
of a treatment region as well as acoustically monitoring the
temperature profile or other tissue parameter monitoring of the
treatment region and the general vicinity thereof. For example, in
accordance with an exemplary embodiment, ultrasound therapy
treatment system 200 may be configured with a dynamic feedback
arrangement based on monitoring of temperature or other tissue
parameters, and/or based on imaging information to suitably adjust
the spatial and/or temporal characteristics of the ultrasound
therapy transducer.
[0039] In order to facilitate imaging, monitoring, treatment and/or
temperature control in ROI 210, control system 204 can be
configured with various components and devices. For example,
Transducer probe 202 can be configured to provide cross sectional
two-dimensional imaging of a region 207, for example as displayed
in an image 205 within a display 206, as well as generate a
controlled thermal lesion 209, confined proximately to Cooper
ligaments and the top of the muscle. Therapeutic ultrasound system
200 can be configured to spare the intervening tissue that contains
vital structures, as well as tissue posterior to conformal lesion
209.
[0040] As previously described, control systems 102 and 204 may be
configured in various manners with various subsystems and
subcomponents. With reference to FIGS. 3A and 3B, in accordance
with exemplary embodiments, an exemplary control system 300 can be
configured for coordination and control of the entire therapeutic
treatment process in accordance with the adjustable settings made
by a therapeutic treatment system user. For example, control system
300 can suitably comprise power source components 302, sensing and
monitoring components 304, cooling and coupling controls 306,
and/or processing and control logic components 308. Control system
300 can be configured and optimized in a variety of ways with more
or less subsystems and components to implement the therapeutic
system for noninvasive mastopexy, and the embodiment in FIGS. 3A
and 3B are merely for illustration purposes.
[0041] For example, for power sourcing components 302, control
system 300 can comprise one or more direct current (DC) power
supplies 303 configured to provide electrical energy for entire
control system 300, including power required by a transducer
electronic amplifier/driver 312. A DC current sense device 305 can
also be provided to confirm the level of power going into
amplifiers/drivers 312 for safety and monitoring purposes.
[0042] Amplifiers/drivers 312 can comprise multi-channel or single
channel power amplifiers and/or drivers. In accordance with an
exemplary embodiment for transducer array configurations,
amplifiers/drivers 312 can also be configured with a beamformer to
facilitate array focusing. An exemplary beamformer can be
electrically excited by an oscillator/digitally controlled waveform
synthesizer 310 with related switching logic.
[0043] The power sourcing components can also include various
filtering configurations 314. For example, switchable harmonic
filters and/or matching may be used at the output of
amplifier/driver 312 to increase the drive efficiency and
effectiveness. Power detection components 316 may also be included
to confirm appropriate operation and calibration. For example,
electric power and other energy detection components 316 may be
used to monitor the amount of power going to an exemplary probe
system.
[0044] Various sensing and monitoring components 304 may also be
suitably implemented within control system 300. For example, in
accordance with an exemplary embodiment, monitoring, sensing and
interface control components 324 may be configured to operate with
various motion detection systems implemented within transducer
probe 104 to receive and process information such as acoustic or
other spatial and temporal information from a region of interest.
Sensing and monitoring components can also include various
controls, interfacing and switches 309 and/or power detectors 316.
Such sensing and monitoring components 304 can facilitate open-loop
and/or closed-loop feedback systems within treatment system
100.
[0045] For example, in such an open-loop system, a system user can
suitably monitor the imaging and or other spatial or temporal
parameters and then adjust or modify same to accomplish a
particular treatment objective. Instead of, or in combination with
open-loop feedback configurations, an exemplary treatment system
can comprise a closed-loop feedback system, wherein images and/or
spatial/temporal parameters can be suitably monitored within
monitoring component to generate signals.
[0046] During operation of exemplary treatment system 100, a lesion
configuration of a selected size, shape, orientation is determined.
Based on that lesion configuration, one or more spatial parameters
are selected, along with suitable temporal parameters, the
combination of which yields the desired conformal lesion. Operation
of the transducer can then be initiated to provide the conformal
lesion or lesions. Open and/or closed-loop feedback systems can
also be implemented to monitor the spatial and/or temporal
characteristics, and/or other tissue parameter monitoring, to
further control the conformal lesions.
[0047] Cooling/coupling control systems 306 may be provided to
remove waste heat from exemplary probe 104, provide a controlled
temperature at the superficial tissue interface and deeper into
tissue, and/or provide acoustic coupling from transducer probe 104
to region-of-interest 106. Such cooling/coupling control systems
306 can also be configured to operate in both open-loop and/or
closed-loop feedback arrangements with various coupling and
feedback components.
[0048] Processing and control logic components 308 can comprise
various system processors and digital control logic 307, such as
one or more of microcontrollers, microprocessors,
field-programmable gate arrays (FPGAs), computer boards, and
associated components, including firmware and control software 326,
which interfaces to user controls and interfacing circuits as well
as input/output circuits and systems for communications, displays,
interfacing, storage, documentation, and other useful functions.
System software and firmware 326 controls all initialization,
timing, level setting, monitoring, safety monitoring, and all other
system functions required to accomplish user-defined treatment
objectives. Further, various control switches 308 can also be
suitably configured to control operation.
[0049] An exemplary transducer probe 104 can also be configured in
various manners and comprise a number of reusable and/or disposable
components and parts in various embodiments to facilitate its
operation. For example, transducer probe 104 can be configured
within any type of transducer probe housing or arrangement for
facilitating the coupling of transducer to a tissue interface, with
such housing comprising various shapes, contours and configurations
depending on the particular treatment application. For example, in
accordance with an exemplary embodiment, transducer probe 104 can
be depressed against a tissue interface whereby blood perfusion is
partially or wholly cut-off, and tissue flattened in superficial
treatment region-of-interest 106. Transducer probe 104 can comprise
any type of matching, such as for example, electric matching, which
may be electrically switchable; multiplexer circuits and/or
aperture/element selection circuits; and/or probe identification
devices, to certify probe handle, electric matching, transducer
usage history and calibration, such as one or more serial EEPROM
(memories). Transducer probe 104 may also comprise cables and
connectors; motion mechanisms, motion sensors and encoders; thermal
monitoring sensors; and/or user control and status related
switches, and indicators such as LEDs. For example, a motion
mechanism in probe 104 may be used to controllably create multiple
lesions, or sensing of probe motion itself may be used to
controllably create multiple lesions and/or stop creation of
lesions, e.g. for safety reasons if probe 104 is suddenly jerked or
is dropped. In addition, an external motion encoder arm may be used
to hold the probe during use, whereby the spatial position and
attitude of probe 104 is sent to the control system to help
controllably create lesions. Furthermore, other sensing
functionality such as profilometers or other imaging modalities may
be integrated into the probe in accordance with various exemplary
embodiments.
[0050] With reference to FIGS. 4A and 4B, in accordance with an
exemplary embodiment, a transducer probe 400 can comprise a control
interface 402, a transducer 404, coupling components 406, and
monitoring/sensing components 408, and/or motion mechanism 410.
However, transducer probe 400 can be configured and optimized in a
variety of ways with more or less parts and components to provide
ultrasound energy for noninvasive mastopexy, and the embodiment in
FIGS. 4A and 4B are merely for illustration purposes.
[0051] In accordance with an exemplary embodiment of the present
invention, transducer probe 400 is configured to deliver energy
over varying temporal and/or spatial distributions in order to
provide energy effects and initiate responses in a region of
interest. These effects can include, for example, thermal,
cavitational, hydrodynamic, and resonance induced tissue effects.
For example, exemplary transducer probe 400 can be operated under
one or more frequency ranges to provide two or more energy effects
and initiate one or more responses in the region of interest. In
addition, transducer probe 400 can also be configured to deliver
planar, defocused and/or focused energy to a region of interest to
provide two or more energy effects and to initiate one or more
reactions. These responses can include, for example, diathermy,
hemostasis, revascularization, angiogenesis, growth of
interconnective tissue, tissue reformation, ablation of existing
tissue, protein synthesis and/or enhanced cell permeability. These
and various other exemplary embodiments for such combined
ultrasound treatment, effects and responses are more fully set
forth in U.S. patent application Ser. No. 10/950,112, entitled
"METHOD AND SYSTEM FOR COMBINED ULTRASOUND TREATMENT," Filed Sep.
24, 2004 and incorporated herein by reference.
[0052] Control interface 402 is configured for interfacing with
control system 300 to facilitate control of transducer probe 400.
Control interface components 402 can comprise multiplexer/aperture
select 424, switchable electric matching networks 426, serial
EEPROMs and/or other processing components and matching and probe
usage information 430 and interface connectors 432.
[0053] Coupling components 406 can comprise various devices to
facilitate coupling of transducer probe 400 to a region of
interest. For example, coupling components 406 can comprise cooling
and acoustic coupling system 420 configured for acoustic coupling
of ultrasound energy and signals. Acoustic cooling/coupling system
420 with possible connections such as manifolds may be utilized to
couple sound into the region-of-interest, control temperature at
the interface and deeper into tissue, provide liquid-filled lens
focusing, and/or to remove transducer waste heat. Coupling system
420 may facilitate such coupling through use of various coupling
mediums, including air and other gases, water and other fluids,
gels, solids, and/or any combination thereof, or any other medium
that allows for signals to be transmitted between transducer active
elements 412 and a region of interest. In addition to providing a
coupling function, in accordance with an exemplary embodiment,
coupling system 420 can also be configured for providing
temperature control during the treatment application. For example,
coupling system 420 can be configured for controlled cooling of an
interface surface or region between transducer probe 400 and a
region of interest and beyond and beyond by suitably controlling
the temperature of the coupling medium. The suitable temperature
for such coupling medium can be achieved in various manners, and
utilize various feedback systems, such as thermocouples,
thermistors or any other device or system configured for
temperature measurement of a coupling medium. Such controlled
cooling can be configured to further facilitate spatial and/or
thermal energy control of transducer probe 400.
[0054] In accordance with an exemplary embodiment, with additional
reference to FIG. 11, acoustic coupling and cooling 1140 can be
provided to acoustically couple energy and imaging signals from
transducer probe 1104 to and from the region of interest 1102, to
provide thermal control at the probe to region-of-interest
interface 1110 and deeper into tissue, and to remove potential
waste heat from the transducer probe at region 1144. Temperature
monitoring can be provided at the coupling interface via a thermal
sensor 1146 to provide a mechanism of temperature measurement 1148
and control via control system 1106 and a thermal control system
1142. Thermal control may consist of passive cooling such as via
heat sinks or natural conduction and convection or via active
cooling such as with peltier thermoelectric coolers, refrigerants,
or fluid-based systems comprised of pump, fluid reservoir, bubble
detection, flow sensor, flow channels/tubing 1144 and thermal
control 1142.
[0055] Monitoring and sensing components 408 can comprise various
motion and/or position sensors 416, temperature monitoring sensors
418, user control and feedback switches 414 and other like
components for facilitating control by control system 300, e.g., to
facilitate spatial and/or temporal control through open-loop and
closed-loop feedback arrangements that monitor various spatial and
temporal characteristics.
[0056] Motion mechanism 410 can comprise manual operation,
mechanical arrangements, or some combination thereof. For example,
a motion mechanism 422 can be suitably controlled by control system
300, such as through the use of accelerometers, encoders or other
position/orientation devices 416 to determine and enable movement
and positions of transducer probe 400. Linear, rotational or
variable movement can be facilitated, e.g., those depending on the
treatment application and tissue contour surface.
[0057] Transducer 404 can comprise one or more transducers
configured for producing conformal lesions of thermal injury in
superficial human tissue within a region of interest through
precise spatial and temporal control of acoustic energy deposition.
Transducer 404 can also comprise one or more transduction elements
and/or lenses 412. The transduction elements can comprise a
piezoelectrically active material, such as lead zirconante titanate
(PZT), or any other piezoelectrically active material, such as a
piezoelectric ceramic, crystal, plastic, and/or composite
materials, as well as lithium niobate, lead titanate, barium
titanate, and/or lead metaniobate. In addition to, or instead of, a
piezoelectrically active material, transducer 404 can comprise any
other materials configured for generating radiation and/or
acoustical energy. Transducer 404 can also comprise one or more
matching layers configured along with the transduction element such
as coupled to the piezoelectrically active material. Acoustic
matching layers and/or damping may be employed as necessary to
achieve the desired electroacoustic response.
[0058] In accordance with an exemplary embodiment, the thickness of
the transduction element of transducer 404 can be configured to be
uniform. That is, a transduction element 412 can be configured to
have a thickness that is substantially the same throughout. In
accordance with another exemplary embodiment, the thickness of a
transduction element 412 can also be configured to be variable. For
example, transduction element(s) 412 of transducer 404 can be
configured to have a first thickness selected to provide a center
operating frequency of a lower range, for example from
approximately 1 MHz to 5 MHz. Transduction element 404 can also be
configured with a second thickness selected to provide a center
operating frequency of a higher range, for example from
approximately 5 MHz to 15 MHz or more. Transducer 404 can be
configured as a single broadband transducer excited with at least
two or more frequencies to provide an adequate output for
generating a desired response. Transducer 404 can also be
configured as two or more individual transducers, wherein each
transducer comprises one or more transduction element. The
thickness of the transduction elements can be configured to provide
center-operating frequencies in a desired treatment range. For
example, transducer 404 can comprise a first transducer configured
with a first transduction element having a thickness corresponding
to a center frequency range of approximately 1 MHz to 5 MHz, and a
second transducer configured with a second transduction element
having a thickness corresponding to a center frequency of
approximately 5 MHz to 15 MHz or more.
[0059] Transducer 404 may be composed of one or more individual
transducers in any combination of focused, planar, or unfocused
single-element, multi-element, or array transducers, including 1-D,
2-D, and annular arrays; linear, curvilinear, sector, or spherical
arrays; spherically, cylindrically, and/or electronically focused,
defocused, and/or lensed sources. For example, with reference to an
exemplary embodiment depicted in FIG. 5, transducer 500 can be
configured as an acoustic array 502 to facilitate phase focusing.
That is, transducer 500 can be configured as an array of electronic
apertures that may be operated by a variety of phases via variable
electronic time delays. By the term "operated," the electronic
apertures of transducer 500 may be manipulated, driven, used,
and/or configured to produce and/or deliver an energy beam
corresponding to the phase variation caused by the electronic time
delay. For example, these phase variations can be used to deliver
defocused beams 508, planar beams 504, and/or focused beams 506,
each of which may be used in combination to achieve different
physiological effects in a region of interest 510. Transducer 500
may additionally comprise any software and/or other hardware for
generating, producing and or driving a phased aperture array with
one or more electronic time delays.
[0060] Transducer 500 can also be configured to provide focused
treatment to one or more regions of interest using various
frequencies. In order to provide focused treatment, transducer 500
can be configured with one or more variable depth devices to
facilitate treatment. For example, transducer 500 may be configured
with variable depth devices disclosed in U.S. patent application
Ser. No. 10/944,500, entitled "System and Method for Variable Depth
Ultrasound", filed on Sep. 16, 2004, having at least one common
inventor and a common Assignee as the present application, and
incorporated herein by reference. In addition, transducer 500 can
also be configured to treat one or more additional ROI 510 through
the enabling of sub-harmonics or pulse-echo imaging, as disclosed
in U.S. patent application Ser. No. 10/944,499, entitled "Method
and System for Ultrasound Treatment with a Multi-directional
Transducer", filed on Sep. 16, 2004, having at least one common
inventor and a common Assignee as the present application, and also
incorporated herein by reference.
[0061] Moreover, any variety of mechanical lenses or variable focus
lenses, e.g. liquid-filled lenses, may also be used to focus and or
defocus the sound field. For example, with reference to exemplary
embodiments depicted in FIGS. 6A and 6B, transducer 600 may also be
configured with an electronic focusing array 604 in combination
with one or more transduction elements 606 to facilitate increased
flexibility in treating ROI 610. Array 604 may be configured in a
manner similar to transducer 502. That is, array 604 can be
configured as an array of electronic apertures that may be operated
by a variety of phases via variable electronic time delays, for
example, T.sub.1, T.sub.2 . . . T.sub.j. By the term "operated,"
the electronic apertures of array 604 may be manipulated, driven,
used, and/or configured to produce and/or deliver energy in a
manner corresponding to the phase variation caused by the
electronic time delay. For example, these phase variations can be
used to deliver defocused beams, planar beams, and/or focused
beams, each of which may be used in combination to achieve
different physiological effects in ROI 610.
[0062] Transduction elements 606 may be configured to be concave,
convex, and/or planar. For example, in an exemplary embodiment
depicted in FIG. 6A, transduction elements 606 are configured to be
concave in order to provide focused energy for treatment of ROI
610. Additional embodiments are disclosed in U.S. patent
application Ser. No. 10/944,500, entitled "Variable Depth
Transducer System and Method", and again incorporated herein by
reference.
[0063] In another exemplary embodiment, depicted in FIG. 6B,
transduction elements 606 can be configured to be substantially
flat in order to provide substantially uniform energy to ROI 610.
While FIGS. 6A and 6B depict exemplary embodiments with
transduction elements 604 configured as concave and substantially
flat, respectively, transduction elements 604 can be configured to
be concave, convex, and/or substantially flat. In addition,
transduction elements 604 can be configured to be any combination
of concave, convex, and/or substantially flat structures. For
example, a first transduction element can be configured to be
concave, while a second transduction element can be configured to
be substantially flat.
[0064] With reference to FIGS. 8A and 8B, transducer 404 can be
configured as single-element arrays, wherein a single-element 802,
e.g., a transduction element of various structures and materials,
can be configured with a plurality of masks 804, such masks
comprising ceramic, metal or any other material or structure for
masking or altering energy distribution from element 802, creating
an array of energy distributions 808. Masks 804 can be coupled
directly to element 802 or separated by a standoff 806, such as any
suitably solid or liquid material.
[0065] An exemplary transducer 404 can also be configured as an
annular array to provide planar, focused and/or defocused
acoustical energy. For example, with reference to FIGS. 10A and
10B, in accordance with an exemplary embodiment, an annular array
1000 can comprise a plurality of rings 1012, 1014, 1016 to N. Rings
1012, 1014, 1016 to N can be mechanically and electrically isolated
into a set of individual elements, and can create planar, focused,
or defocused waves. For example, such waves can be centered
on-axis, such as by methods of adjusting corresponding transmit
and/or receive delays, .tau..sub.1, .tau..sub.2, .tau..sub.3 . . .
.tau..sub.N. An electronic focus can be suitably moved along
various depth positions, and can enable variable strength or beam
tightness, while an electronic defocus can have varying amounts of
defocusing. In accordance with an exemplary embodiment, a lens
and/or convex or concave shaped annular array 1000 can also be
provided to aid focusing or defocusing such that any time
differential delays can be reduced. Movement of annular array 1000
in one, two or three-dimensions, or along any path, such as through
use of probes and/or any conventional robotic arm mechanisms, may
be implemented to scan and/or treat a volume or any corresponding
space within a region of interest.
[0066] Transducer 404 can also be configured in other annular or
non-array configurations for imaging/therapy functions. For
example, with reference to FIGS. 10C-10F, a transducer can comprise
an imaging element 1012 configured with therapy element(s) 1014.
Elements 1012 and 1014 can comprise a single-transduction element,
e.g., a combined imaging/transducer element, or separate elements,
can be electrically isolated 1022 within the same transduction
element or between separate imaging and therapy elements, and/or
can comprise standoff 1024 or other matching layers, or any
combination thereof. For example, with particular reference to FIG.
10F, a transducer can comprise an imaging element 1012 having a
surface 1028 configured for focusing, defocusing or planar energy
distribution, with therapy elements 1014 including a
stepped-configuration lens configured for focusing, defocusing, or
planar energy distribution.
[0067] In accordance with another aspect of the invention,
transducer probe 400 may be configured to provide one, two or
three-dimensional treatment applications for focusing acoustic
energy to one or more regions of interest. For example, as
discussed above, transducer probe 400 can be suitably diced to form
a one-dimensional array, e.g., a transducer comprising a single
array of sub-transduction elements.
[0068] In accordance with another exemplary embodiment, transducer
probe 400 may be suitably diced in two-dimensions to form a
two-dimensional array. For example, with reference to FIG. 9, an
exemplary two-dimensional array 900 can be suitably diced into a
plurality of two-dimensional portions 902. Two-dimensional portions
902 can be suitably configured to focus on the treatment region at
a certain depth, and thus provide respective slices 904 of the
treatment region. As a result, the two-dimensional array 900 can
provide a two-dimensional slicing of the image place of a treatment
region, thus providing two-dimensional treatment.
[0069] In accordance with another exemplary embodiment, transducer
probe 400 may be suitably configured to provide three-dimensional
treatment. For example, to provide three dimensional treatment of a
region of interest, with reference again to FIG. 3, a
three-dimensional system can comprise transducer probe 400
configured with an adaptive algorithm, such as, for example, one
utilizing three-dimensional graphic software, contained in a
control system, such as control system 300. The adaptive algorithm
is suitably configured to receive two-dimensional imaging,
temperature and/or treatment information relating to the region of
interest, process the received information, and then provide
corresponding three-dimensional imaging, temperature and/or
treatment information.
[0070] In accordance with an exemplary embodiment, with reference
again to FIG. 9, an exemplary three-dimensional system can comprise
a two-dimensional array 900 configured with an adaptive algorithm
to suitably receive 904. 907 slices from different image planes of
the treatment region, process the received information, and then
provide volumetric information 906, e.g., three-dimensional
imaging, temperature and/or treatment information. Moreover, after
processing the received information with the adaptive algorithm,
the two-dimensional array 900 may suitably provide therapeutic
heating to the volumetric region 906 as desired.
[0071] Alternatively, rather than utilizing an adaptive algorithm,
such as three-dimensional software, to provide three-dimensional
imaging and/or temperature information, an exemplary
three-dimensional system can comprise a single transducer 404
configured within a probe arrangement to operate from various
rotational and/or translational positions relative to a target
region.
[0072] To further illustrate the various structures for transducer
404, with reference to FIG. 7, ultrasound therapy transducer 700
can be configured for a single focus, an array of foci, a locus of
foci, a line focus, and/or diffraction patterns. Transducer 700 can
also comprise single elements, multiple elements, annular arrays,
one-, two-, or three-dimensional arrays, broadband transducers,
and/or combinations thereof, with or without lenses, acoustic
components, and mechanical and/or electronic focusing. Transducers
configured as spherically focused single elements 702, annular
arrays 704, annular arrays with damped regions 706, line focused
single elements 708, 1-D linear arrays 710, 1-D curvilinear arrays
in concave or convex form, with or without elevation focusing, 2-D
arrays, and 3-D spatial arrangements of transducers may be used to
perform therapy and/or imaging and acoustic monitoring functions.
For any transducer configuration, focusing and/or defocusing may be
in one plane or two planes via mechanical focus 720, convex lens
722, concave lens 724, compound or multiple lenses 726, planar form
728, or stepped form, such as illustrated in FIG. 10F. Any
transducer or combination of transducers may be utilized for
treatment. For example, an annular transducer may be used with an
outer portion dedicated to therapy and the inner disk dedicated to
broadband imaging wherein such imaging transducer and therapy
transducer have different acoustic lenses and design, such as
illustrated in FIG. 10C-10F.
[0073] Various shaped treatment lesions can be produced using the
various acoustic lenses and designs in FIGS. 10A-10F. For example,
cigar-shaped lesions may be produced from a spherically focused
source, and/or planar lesions from a flat source. Concave planar
sources and arrays can produce a "V-shaped" or ellipsoidal lesion.
Electronic arrays, such as a linear array, can produce defocused,
planar, or focused acoustic beams that may be employed to form a
wide variety of additional lesion shapes at various depths. An
array may be employed alone or in conjunction with one or more
planar or focused transducers. Such transducers and arrays in
combination produce a very wide range of acoustic fields and their
associated benefits. A fixed focus and/or variable focus lens or
lenses may be used to further increase treatment flexibility. A
convex-shaped lens, with acoustic velocity less than that of
superficial tissue, may be utilized, such as a liquid-filled lens,
gel-filled or solid gel lens, rubber or composite lens, with
adequate power handling capacity; or a concave-shaped, low profile,
lens may be utilized and composed of any material or composite with
velocity greater than that of tissue. While the structure of
transducer source and configuration can facilitate a particular
shaped lesion as suggested above, such structures are not limited
to those particular shapes as the other spatial parameters, as well
as the temporal parameters, can facilitate additional shapes within
any transducer structure and source.
[0074] Through operation of ultrasound system 100, a method for
mastopexy can be realized that can facilitate effective and
efficient therapy without creating chronic injury to human tissue.
For example, a user may first select one or more transducer probe
configurations for treating a region of interest. The user may
select any probe configuration described herein. Because the
treatment region ranges from approximately 1 mm to 4 cm, exemplary
transducer probes may include, for example, an annular array, a
variable depth transducer, a mechanically moveable transducer, a
cylindrical-shaped transducer, and the like. As used herein, the
term user may include a person, employee, doctor, nurse, and/or
technician, utilizing any hardware and/or software of other control
systems.
[0075] Once one or more transducers are selected, the user may then
image a region of interest in order to plan a treatment protocol.
By imaging a region of interest, the user may user the same
treatment transducer probe and/or one or more additional
transducers to image the region of interest at a high resolution.
In one embodiment, the transducer may be configured to facilitate
high speed imaging over a large region of interest to enable
accurate imaging over a large region of interest. In another
embodiment, ultrasound imaging may include the use of Doppler flow
monitoring and/or color flow monitoring. In addition other means of
imaging such as photography and other visual optical methods, MRI,
X-Ray, PET, infrared or others can be utilized separately or in
combination for imaging and feedback of the superficial tissue and
the vascular tissue in the region of interest.
[0076] In accordance with another exemplary embodiment, with
reference to FIG. 12, an exemplary treatment system 200 can be
configured with and/or combined with various auxiliary systems to
provide additional functions. For example, an exemplary treatment
system 1200 for treating a region of interest 1202 can comprise a
control system 1206, a probe 1204, and a display 1208. Treatment
system 1200 further comprises an auxiliary imaging modality 1274
and/or auxiliary monitoring modality 1272 may be based upon at
least one of photography and other visual optical methods, magnetic
resonance imaging (MRI), computed tomography (CT), optical
coherence tomography (OCT), electromagnetic, microwave, or radio
frequency (RF) methods, positron emission tomography (PET),
infrared, ultrasound, acoustic, or any other suitable method of
visualization, localization, or monitoring of region-of-interest
1202, including imaging/monitoring enhancements. Such
imaging/monitoring enhancement for ultrasound imaging via probe
1204 and control system 1206 could comprise M-mode, persistence,
filtering, color, Doppler, and harmonic imaging among others;
furthermore an ultrasound treatment system 1270, as a primary
source of treatment, may be combined with a secondary source of
treatment 1276, including radio frequency (RF), intense pulsed
light (IPL), laser, infrared laser, microwave, or any other
suitable energy source.
[0077] Because the location of Cooper's ligaments varies from one
patient to another (due to genetics, weight, age, etc.), high speed
imaging using a transducer can facilitate tracking the depth of
treatment within a patient, imaging the ligament variations within
the chest, and/or determining the length and/or location of one or
more Cooper's ligaments within a patient. This
imaging/tracking/determining information can also be used to
calculate the optimal shrinkage of the Cooper's ligaments needed to
facilitate the desired level of mastopexic results.
[0078] By planning a treatment protocol, the user may choose one or
more spatial and/or temporal characteristics to provide conformal
ultrasound energy to a region of interest. For example, the user
may select one or more spatial characteristics to control,
including, for example, the use one or more transducers, one or
more mechanical and/or electronic focusing mechanisms, one or more
transduction elements, one or more placement locations of the
transducer relative to the region of interest, one or more feedback
systems, one or more mechanical arms, one or more orientations of
the transducer, one or more temperatures of treatment, one or more
coupling mechanisms and/or the like.
[0079] In addition, the user may choose one or more temporal
characteristics to control in order to facilitate treatment of the
region of interest. For example, the user may select and/or vary
the treatment time, frequency, power, energy, amplitude and/or the
like in order to facilitate temporal control. For more information
on selecting and controlling ultrasound spatial and temporal
characteristics, see U.S. application Ser. No. 10/163,148, entitled
"Method and System for Controlled Thermal Injury," filed Oct. 6,
2005 and incorporated herein by reference.
[0080] After planning of a treatment protocol is complete, the
treatment protocol can be implemented. That is, a transducer system
can be used to deliver ultrasound energy to a treatment region to
ablate select tissue in order to facilitate mastopexy. By
delivering energy, the transducer may be driven at a select
frequency, a phased array may be driven with certain temporal
and/or spatial distributions, a transducer may be configured with
one or more transduction elements to provide focused, defocused
and/or planar energy, and/or the transducer may be configured
and/or driven in any other ways hereinafter devised.
[0081] In one exemplary embodiment, energy is delivered in
relatively small ablative areas in order to minimize and/or prevent
scar tissue from forming. That is, each ablative area of treatment
can range from approximately sub-millimeter to several millimeters
in size.
[0082] In one exemplary embodiment, energy is delivered at a
treatment depth of approximately 1 mm to 4 cm. The energy may range
from 1 MHz to about 15 MHz, with typical applications ranging from
2 MHz to 8 MHz. In order to deliver energy in this treatment range,
the transducer can be driven at power levels ranging from 10 W to
150 W or more. Because of the high power and focused treatment that
the transducer provides, treatment times for a region of interest
can range from 20 milliseconds to 2000 milliseconds or more.
Because treatment time and treatment power are interrelated, these
variables may differ from one patient to another and/or from one
region of interest to another.
[0083] Once the treatment protocol has been implemented, the region
of tissue may have one or more responses in reaction to the
treatment. For example, in one embodiment, the tissue responds by
causing additional contraction of the Cooper's ligaments and/or
other treatment tissues.
[0084] Upon treatment, the steps outlined above can be repeated one
or more additional times to provide for optimal treatment results.
Different ablation sizes and shapes may affect the recovery time
and time between treatments. For example, in general, the larger
the surface area of the treatment lesion, the faster the recovery.
The series of treatments can also enable the user to tailor
additional treatments in response to a patient's responses to the
ultrasound treatment.
[0085] The present invention has been described above with
reference to various exemplary embodiments. However, those skilled
in the art will recognize that changes and modifications may be
made to the exemplary embodiments without departing from the scope
of the present invention. For example, the various operational
steps, as well as the components for carrying out the operational
steps, may be implemented in alternate ways depending upon the
particular application or in consideration of any number of cost
functions associated with the operation of the system, e.g.,
various steps may be deleted, modified, or combined with other
steps. These and other changes or modifications are intended to be
included within the scope of the present invention, as set forth in
the following claims.
* * * * *